Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats

dc.authoridBAHCIVAN, Emre/0000-0002-4415-1738
dc.authoridUney, Kamil/0000-0002-8674-4873
dc.contributor.authorDik, Burak
dc.contributor.authorCoskun, Devran
dc.contributor.authorBahcivan, Emre
dc.contributor.authorUney, Kamil
dc.date.accessioned2024-12-24T19:33:57Z
dc.date.available2024-12-24T19:33:57Z
dc.date.issued2021
dc.departmentSiirt Üniversitesi
dc.description.abstractAim: The aim of this study is to determine the effects of different concentrations of albendazole and lansoprazole, which were benzimidazole derivatives, on endocrinologic and biochemical parameters in experimental type 2 diabetic (T2D) rats. Materials and methods: In this study, 46 male Wistar Albino rats were used. Animals were divided as healthy control (0.1 mL/rat/day saline, s.c, n = 6), diabetes control (0.1 mL/rat/day saline, s.c, n = 8), diabetes+low-dose albendazole (5 mg/kg, oral, n = 8), diabetes+high-dose albendazole (10 mg/kg, oral n = 8), diabetes+low-dose lansoprazole (15 mg/kg, subcutaneous, n = 8), and diabetes+high-dose lansoprazole (30 mg/kg, subcutaneous, n = 8). All groups were treated for 8 weeks. The blood samples were analyzed by autoanalyzer and ELISA kits for biochemical and endocrinological parameters, respectively. Results: Glucose, HbA1c, triglyceride, low density cholesterol (LDL), leptin, and Homeostatic Model Assessment for insulin resistance (HOMA-IR) levels increased and insulin and HOMA-beta levels decreased in the diabetic rats compared to the healthy control group. The glucose, HbA1c, and triglyceride levels were partially decreased; however, insulin and HOMA-beta levels were increased by low-dose albendazole therapy. The high dose of lansoprazole treatment increased insulin level. Conclusion: The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D treatment by Adenosine 5'-monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), incretin-like effect and other antidiabetic mechanisms. It may be beneficial to create an effective treatment strategy by developing more specific substances with benzimidazole scaffold.
dc.description.sponsorshipSUPABK [17401179]
dc.description.sponsorshipThis research was supported by SUPABK with 17401179 project numbers. The abstract of the study will present at the 1st International Veterinary Pharmacology and Toxicology Congress, in Kayseri, Turkey.
dc.identifier.doi10.3906/sag-2004-38
dc.identifier.endpage1586
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue3
dc.identifier.pmid33641315
dc.identifier.scopus2-s2.0-85109811700
dc.identifier.scopusqualityQ1
dc.identifier.startpage1579
dc.identifier.trdizinid483350
dc.identifier.urihttps://doi.org/10.3906/sag-2004-38
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/483350
dc.identifier.urihttps://hdl.handle.net/20.500.12604/8349
dc.identifier.volume51
dc.identifier.wosWOS:000668257500020
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241222
dc.subjectBenzimidazole
dc.subjectHOMA-beta
dc.subjectdiabetes
dc.subjectantiabetic
dc.subjectrat
dc.titlePotential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Tam Metin / Full Text
Boyut:
195.14 KB
Biçim:
Adobe Portable Document Format